The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
Commentary|Videos|April 15, 2024
Dr. Goswami's Oncology Journey: Patient-centric Science and Mentorship Stories
Author(s)Sangeeta Goswami, MD, PhD
Sangeeta Goswami, MD, PhD, discusses her career focused in genitourinary cancers, with a focus on patient-centric science and shares mentorship stories along the way.
Advertisement
Sangeeta Goswami, MD, PhD, discusses her career focused in genitourinary cancers, with a focus on patient-centric science and shares mentorship stories along the way.
Advertisement
Related to this article
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma
3
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
4
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
5